News Room
News Releases
-
- Jan. 10, 2019 (PDF/86KB)R&D
-
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase III Clinical Study (JEWEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
-
- Dec. 28, 2018 (PDF/72KB)Corporate
-
Correction to "Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S."
-
- Dec. 25, 2018 (PDF/103KB)Corporate
-
Merger of DS Pharma Biomedical and DS Pharma Promo
-
- Dec. 21, 2018 (PDF/127KB)R&D
-
Kyoto University's Center for iPS Cell Research and Application, Sumitomo Chemical, and Sumitomo Dainippon Pharma Commence Joint Research on Producing Higher-Quality iPS Cells for Clinical Use
-
- Dec. 05, 2018 (PDF/39KB)Corporate
-
Sumitomo Dainippon Pharma Announces Resolution of Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S.
-
- Nov. 27, 2018 (PDF/40KB)Corporate
-
Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S. (Partial correction on December 28, 2018)
-
- Nov. 27, 2018 (PDF/40KB)Corporate
-
Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S.
-
- Nov. 27, 2018CSR
-
Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
-
- Nov. 20, 2018 (PDF/2,067KB)CSR
-
ESG Meeting (Discussion with Investors)
-
- Nov. 12, 2018 (PDF/127KB)Related Business
-
Announcement of the establishment of new joint company by Sumitomo Bakelite Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd.
Documents for Press
-
- Dec. 02, 2013 (PDF/414KB)R&D
-
Presentation material of press conference (Healios and DSP: Alliance for Japanese market-iPS cell technology into practical use-)